Compared with its use for chronic pain, reliable evidence to support the use of cannabis to treat anxiety is lacking and available data are “conflicting.” To bring clarity to the issue, researchers conducted a retrospective database study of Canadian medical cannabis patients.
Researchers conducted a meta-analysis of double-blind RCTs of nabiximols and placebo treatments for chronic, noncancer neuropathic pain.
A survey of 100 cancer patients revealed a high interest in CBD use, but most patients would prefer receiving more information from qualified sources.
Older adults with functional impairments may be more likely to misuse prescription drugs and to use medical cannabis.
Higher rates of cannabis product exposures reported to US poison control centers are seen in states where marijuana is legal, suggesting that exposures may be expected to increase with expanded legalization in more states.
The researchers aimed to determine the efficacy and withdrawal rates of therapies used to manage the chronic pain of spinal cord injury as well as the incidence of adverse events.
Though patient use of cannabinoids for the treatment of IBD has increased, clinical decision making on whether to formally recommend it as treatment remains difficult.
There is a negative association between medical and recreational cannabis stores (dispensaries) and opioid-related mortality.
Two expert physicians with opposing viewpoints debate the risks and benefits of using cannabinoids for treating neuropathic and chronic pain.
Although studies have shown cannabis reduces pain and has opioid-sparing effects, a large-scale longitudinal clinical study on the effects of cannabis products on patients was needed.
